Antimalarial drugs: current status and new developments

Bibliography

• SHERMAN IW: Malaria : parasite biology, pathogenesis, and protection. ASM Press, Washington DC, USA (1998) xiii:575.
   Google Scholar
• BEADLE C, HOFFMAN SL: History of malaria in the United States Naval Forces at war: World War I through the Vietnam conflict. Clin. Infect. Dis. (1993) 16(2):320–329.
   PubMed Web of Science ®Google Scholar
• KUMAR S, EPSTEIN JE, RICHIE TL et al.: A multilateral effort to develop DNA vaccines against falciparum malaria. Trends Parasitol (2002) 18(3):129–135.
   PubMed Web of Science ®Google Scholar
• PUKRITTAYAKAMEE S, SUPANARANOND W, LOOAREESUWAN S, VANIJANONTA S, WHITE NJ: Quinine in severe falciparum malaria: evidence of declining efficacy in Thailand. Trans. R. Soc. Trop. Med. Hyg. (1994) 88(3):324–327.
   PubMed Web of Science ®Google Scholar
• JELINEK T, SCHELBERT P, LOSCHERT, EICHENLAUB D: Quinine resistant falciparum malaria acquired in east Africa. Trop. Med. Parasitol. (1995) 46(1):38–40.
   PubMedGoogle Scholar
• SEGURADO AA, DI SANTI SM, SHIROMA M: In vivo and in vitro Plasmodium falciparum resistance to chloroquine, amodiaquine and quinine in the Brazilian Amazon. Rev Inst. Med. Trop. Sao Paulo (1997) 39(2):85–90.
   PubMedGoogle Scholar
• SULLIVAN DJ Jr, GLUZMAN IY, GOLDBERG DE: Plasmodium hemozoin formation mediated by histidine-rich proteins. Science (1996) 271(5246):219–222.
   PubMed Web of Science ®Google Scholar
• CHONG CR, SULLIVAN DJ Jr: Inhibition of heme crystal growth by antimalarials and other compounds: implications for drug discovery. Biochem. Pharmacol (2003) 66(11):2201–2212.
   PubMed Web of Science ®Google Scholar
• FIDOCK DA, NOMURA T, TALLEY AK et al.: Mutations in the R falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell (2000) 6(4)861–871.
   Google Scholar
• WOOTTON JC, FENG X, FERDIG MT et al: Genetic diversity and chloroquine selective sweeps in Plasmodium falciparum. Nature (2002) 418(6895):320–323.
   PubMed Web of Science ®Google Scholar
• NOMURA T, CARLTON JM, BAIRD JK et al: Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. I Infect. Dis. (2001) 183(11):1653–1661.
   PubMed Web of Science ®Google Scholar
• SMRKOVSKI LL, BUCK RL, ALCANTARA AK, RODRIGUEZ CS, UYLANGCO CV: Studies of resistance to chloroquine, quinine, amodiaquine and mefloquine among Philippine strains of Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg. (1985) 79(1):37–41.
   PubMed Web of Science ®Google Scholar
• SMRKOVSKI LL, BUCK RL, RODRIGUEZ CS et al: Chloroquine and quinine resistant Plasmodium fakiparum on the island of Mindoro, Philippines, 1982. Southeast Asian J. Trop. Med. Public Health (1982) 13(4):551–555.
   PubMedGoogle Scholar
• ADJUIK M, AGNAMEY P, BABIKER A et al: Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet (2002) 359(9315):1365–1372.
   PubMed Web of Science ®Google Scholar
• EANMAT: The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop. Med. Int. Health (2003) 8(10):860–867.
   PubMed Web of Science ®Google Scholar
• O'NEILL PM, MUKHTAR A, STOCKS PA et al: Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J. Med. Chem. (2003) 46(23):4933–4945.
   PubMed Web of Science ®Google Scholar
• ATTEKE C, NDONG JM, AUBOUY A et al: In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooue region of Gabon. J. Antimicrob. Chemother. (2003) 51(4):1021–1024.
   PubMed Web of Science ®Google Scholar
• CHEN L, QU FY, ZHOU YC: Field observations on the antimalarial piperaquine. ChM Med. J. (Engl.) (1982) 95(4):281–286.
   PubMed Web of Science ®Google Scholar
• CHEN L: Recent studies on antimalarial efficacy of piperaquine and hydroxypiperaquine. ChM. Med.'ngl.) (1991) 104(2):161–163.
   Google Scholar
• LAN CX, LIN X, HUANG ZS, CHEN YS, GUO RN: In vivosensitivity of Plasmodium falciparum to piperaquine phosphate assayed in Linshui and Baisha counties, Hainan Province. ZhongguoJi Sheng Chong Xue _Yu Ji Sheng Chong Bing Za Zhi (1989) 7(3):163–165.
   PubMedGoogle Scholar
• YANG H, LIU D, HUANG K et al: Assay of sensitivity of Plasmodium falciparum to chloroquine, amodiaquine, piperaquine, mefloquine and quinine in Yunnan province. Zhonggudli Sheng Chong Xue Vuji Sheng Chong Bing Za Zhi (1999) 17(1):43–45.
   PubMedGoogle Scholar
• DAVIS TM, HUNG TY, SIM IK, KARUNAJEEWA HA, ILETT KF: Piperaquine: a resurgent antimalarial drug. Drugs (2005) 65(1):75–87.
   PubMed Web of Science ®Google Scholar
• KARUNAJEEWA H, LIM C, HUNG TY et al.: Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. BE I Clin. Pharmacol (2004) 57(1):93–99.
   PubMed Web of Science ®Google Scholar
• DENIS MB, DAVIS TM, HEWITT S et al.: Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. OM Infect. Dis. (2002) 35(12):1469–1476.
   Web of Science ®Google Scholar
• HUNG TY, DAVIS TM, ILETT KF et al: Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. BE J Clin. Pharmacol (2004) 57(3):253–262.
   PubMed Web of Science ®Google Scholar
• TRAN TH, DOLECEK C, PHAM PM et al.: Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial. Lancet (2004)363(9402):18–22.
   PubMed Web of Science ®Google Scholar
• ASHLEY EA, KRUDSOOD S, PHAIPHUN L et al: Randomized, controlled dose-optimization studies of dihydroartemisinin-piperaquine for the treatment of uncomplicated multidrug-resistant falciparum malaria in Thailand. J. Infect. Dis. (2004) 190(101773–1782.
   Google Scholar
• RINGWALD P, BICKII J, BASCO L: Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet (1996) 347(8993):24–28.
   PubMed Web of Science ®Google Scholar
• LOOAREESU WAN S, KYLE DE, VIRAVAN C et al.: Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am. I Trop. Med. Hyg. (1996) 54(2):205–209.
   PubMed Web of Science ®Google Scholar
• NOSTEN F, TER KUILE F, CHONGSUPHAJAISIDDHI T et al: Mefloquine-resistant falciparum malaria on the Thai-Burmese border. Lancet (1991) 337(8750):1140–1143.
   PubMed Web of Science ®Google Scholar
• PRICE RN, UHLEMANN AC, BROCKMAN A et al: Mefloquine resistance in Plasmodium falciparum and increased pfmdr 1 gene copy number. Lancet (2004) 364(9432):438–447.
   PubMed Web of Science ®Google Scholar
• NOSTEN F, VAN VUGT M, PRICE R et al.: Effects of artesunate-mefloquine combination on incidence of Plasmodium fakiparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet (2000) 356(9226):297–302.
   PubMed Web of Science ®Google Scholar
• PRADINES B, TALL A, FUSAI T et al: In vitro activities of benflumetol against 158 Senegalese isolates of Plasmodium fakiparum in comparison with those of standard antimalarial drugs. Antimicrob. Agents Chemother. (1999) 43(2):418–420.
   PubMed Web of Science ®Google Scholar
• VON SEIDLEIN L, JAFFAR S, PINDER M et al: Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J. Infect. Dis. (1997) 176(4):1113–1116.
   PubMed Web of Science ®Google Scholar
• KSHIRSAGAR NA, GOGTAY NJ, MOORTHY NS et al.: A randomized, double-blind, parallel-group, comparative safety, and efficacy trial of oral co-artemether versus oral chloroquine in the treatment of acute uncomplicated Plasmodium fakiparum malaria in adults in India. Am. I Trop. Med. Hyg. (2000) 62(3):402–408.
   PubMed Web of Science ®Google Scholar
• VUGT MV, WILAIRATANA P, GEMPERLI B et al: Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium fakiparum malaria. Am. I Trop. Med. Hyg. (1999) 60(6):936–942.
   PubMed Web of Science ®Google Scholar
• KANEKO A, TALEO G, KALKOA M et al.: Malaria eradication on islands. Lancet (2000) 356(9241):1560–1564.
   PubMed Web of Science ®Google Scholar
• SOTO J, TOLEDO J, RODRIQUEZ M et al.: Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. (1998) 129(3):241–244.
   PubMed Web of Science ®Google Scholar
• SOTO J, TOLEDO J, RODRIQUEZ M et al.: Double-blind, randomized, placebo-controlled assessment of chloroquine/ primaquine prophylaxis for malaria in nonimmune Colombian soldiers. Clin. Infect. Dis. (1999) 29(1):199–201.
   PubMed Web of Science ®Google Scholar
• WALSH DS, LOOAREESUWAN S, WILAIRATANA P et al.: Randomized dose-ranging study of the safety and efficacy of WR-238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand. ./. Infect. Dis. (1999) 180(01282–1287.
   PubMed Web of Science ®Google Scholar
• LELL B, FAUCHER JF, MISSINOU MA et al.: Malaria chemoprophylaxis with tafenoquine: a randomised study. Lancet (2000) 355(9220):2041–2045.
   PubMed Web of Science ®Google Scholar
• EDSTEIN MD, KOCISKO DA, BREWER TG et al.: Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers. BE J. Pharmacol. (2001) 52(6):663–670.
   Web of Science ®Google Scholar
• GOLDBERG DE, SLATER AF, CERAMI A, HENDERSON GB: Hemoglobin degradation in the malaria parasite Plasmodium falciparum: an ordered process in a unique organelle. Proc. Natl. Acad. Sci. USA (1990) 87(8):2931–2935.
   PubMed Web of Science ®Google Scholar
• GOLDBERG DE, SLATER AF, BEAVIS R et al.: Hemoglobin degradation in the human malaria pathogen Plasmodium falciparum: a catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. (1991) 173(4):961–969.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL PJ, LEE GK, SMITH RE: Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest. (1993) 91(3):1052–1056.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL PJ: Proteases of malaria parasites: new targets for chemotherapy. Emerg. Infect. Dis. (1998) 4(1):49–57.
   PubMed Web of Science ®Google Scholar
• EGGLESON KK, DUFFIN KL, GOLDBERG DE: Identification and characterization of falcilysin, a metallopeptidase involved in hemoglobin catabolism within the malaria parasite Plasmodium falciparum. J. Biol. Chem. (1999) 274(45):32411–32417.
   PubMed Web of Science ®Google Scholar
• BANERJEE R, LIU J, BEATTY W Four plasmepsins are active in the Plasmodium falciparum food vacuole, including a protease with an active-site histidine. Proc. Natl. Acad. Li. USA (2002) 99(2):990–995.
   PubMed Web of Science ®Google Scholar
• HAQUE TS, SKILLMAN AG, LEE CE et al: Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. I Med. Chem. (1999) 42(8):1428–1440.
   PubMed Web of Science ®Google Scholar
• CARCACHE DA, HORTNER SR, BERTOGG A et al.: Be novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II. Chembiochem. (2002) 3(11):1137–1141.
   PubMed Web of Science ®Google Scholar
• OLSON JE, LEE GK, SEMENOV A, ROSENTHAL PJ: Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg. Med. Chem. (1999) 7(4):633–638.
   PubMed Web of Science ®Google Scholar
• FUNGLADDA W, HONRADO ER, THIMASARN K et al.: Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull. World Health Organ. (1998) 76\(Suppl. 1):59–66.
   Google Scholar
• KREMSNER PG, WINKLER S, BRANDTS C et al.: Clindamycin in combination with chloroquine or quinine is an effective therapy for uncomplicated Plasmodium falciparum malaria in children from Gabon. ./. Infect. Dis. (1994) 169(2):467–470.
   PubMed Web of Science ®Google Scholar
• ANDERSON SL, BERMAN J, KUSCHNER R et al: Prophylaxis of Plasmodium falciparum malaria with azithromycin administered to volunteers. Ann. Intern. Med. (1995) 123(10):771–773.
   PubMed Web of Science ®Google Scholar
• BOZDECH Z, LLINAS M, PULLIAM BL et al: The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum. PLoS Biol. (2003) 1(1):E5.
   PubMed Web of Science ®Google Scholar
• WALLER RE KEELING PJ, DONALD RG et al.: Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium fakiparum. Proc. Nati Acad. Sci. USA (1998) 95(21):12352–12357.881
   Google Scholar
• SUROLIA N, SUROLIA A: Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. (2001) 7(2):167–173.
   PubMed Web of Science ®Google Scholar
• ••This article elegantly describes thepotential of triclosan as an antimalarial and its mode of action.
   Google Scholar
• McMURRY LM, OETHINGER M, LEVY SB: Triclosan targets lipid synthesis. Nature (1998) 394(6693):531–532.
   PubMed Web of Science ®Google Scholar
• KUO MR, MORBID ONI HR, ALLAND D et al: Targeting tuberculosis and malaria through inhibition of enoyl reductase: compound activity and structural data. J. Biol. Chem. (2003) 278(23):20851–20859.
   PubMed Web of Science ®Google Scholar
• JOMAA H, WIESNER J, SANDERBRAND S et al: Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (1999) 285(5433):1573–1576.
   PubMed Web of Science ®Google Scholar
• MISSINOU MA, BORRMANN S, SCHINDLER A et al: Fosmidomycin for malaria. Lancet (2002) 360(9349):1941–1942.
   PubMed Web of Science ®Google Scholar
• WIESNER J, HENSCHKER D, HUTCHINSON DB, BECK E, JOMAA H: In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob. Agents Chemother. (2002) 46(9):2889–2894.
   PubMed Web of Science ®Google Scholar
• BORRMANN S, ADEGNIKA AA, MATSIEGUI PB et al: Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. ./. Infect. Dis. (2004) 189(5):901–908.
   PubMed Web of Science ®Google Scholar
• BORRMANN S, ISSIFOU S, ESSER G et al.: Fosmidomycin-clindamycin for the treatment of Plasmodium fakiparum malaria../. Infect. Dis. (2004) 190(9):1534–1540.
   Google Scholar
• STROHL WR, FLOSS HG: Thiopeptides. Biotechnology (1995) 28:223–238.
   PubMedGoogle Scholar
• ROGERS MJ, CUNDLIFFE E, McCUTCHAN TF: The antibiotic micrococcin is a potent inhibitor of growth and protein synthesis in the malaria parasite. Antimicrob. Agents Chemother. (1998) 42(3):715–716.
   PubMed Web of Science ®Google Scholar
• FRY M, PUDNEY M: Site of action of the antimalarial hydroxynaphthoquinone, 2-(trans-4-14'-chlorophenyll cyclohexyl)-3-hydroxy-1,4-naphthoquinone (566C80). Biochem. Pharmacol (1992) 43(7):1545–1553.
   PubMed Web of Science ®Google Scholar
• SRIVASTAVA IK, ROTTENBERG H, VAIDYA AB: Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. .1 Biol. Chem. (1997) 272(7):3961–3966.
   Google Scholar
• ITTARAT I, ASAWAMAHASAKDA W, BARTLETT MS, SMITH JW, MESHNICK SR: Effects of atovaquone and other inhibitors on Pneumocystis carinii dihydroorotate dehydrogenase. Antimicrob. Agents Chemother. (1995) 39(2):325–328.
   PubMed Web of Science ®Google Scholar
• HUDSON AT, DICKINS M, GINGER CD et al: 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients. Drugs Exp. Clin. Res. (1991) 17(9):427–435.
   PubMedGoogle Scholar
• CHIODINI PL, CONLON CP, HUTCHINSON DB et al: Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J. Antimicrob. Chemother. (1995) 36(6):1073–1078.
   PubMed Web of Science ®Google Scholar
• LOOAREESUWAN S, VIRAVAN C, WEBSTER HK et al: Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am. J. Trop. Med. Hyg. (1996) 54(1):62–66.
   PubMed Web of Science ®Google Scholar
• SHANKS GD, GORDON DM, KLOTZ FW et al: Efficacy and safety of atovaquone/proguanil as suppressive prophylaxis for Plasmodium falciparum malaria. Clin. Infect. Dis. (1998) 27(3):494–499.
   PubMed Web of Science ®Google Scholar
• LELL B, LUCKNER D, NDJAVE M, SCOTT T, KREMSNER PG: Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet (1998) 351(9104):709–713.
   PubMed Web of Science ®Google Scholar
• SUKWA TY, MULENGA M, CHISDAKA N, ROSKELL NS, SCOTT TR: A randomized, double-blind, Placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone/proguanil) for the prophylaxis of malaria in Zambia. Am. I Trop. Med. Hyg. (1999) 60(4):521–525.
   PubMed Web of Science ®Google Scholar
• SRI VASTAVA IK, MORRISEY JM, DARROUZET E, DALDAL F, VAIDYA AB: Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol (1999) 33(4):704–711.
   PubMed Web of Science ®Google Scholar
• YEATES C: DB-289 Immtech International. 'Drugs (2003) 6(11):1086–1093.
   PubMed Web of Science ®Google Scholar
• LANTERI CA, TRUMPOWER BL, TIDWELL RR, MESHNICK SR: DB-75, a novel trypanocidal agent, disrupts mitochondrial function in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. (2004) 48(10):3968–3974.
   PubMed Web of Science ®Google Scholar
• MEDICINES FOR MALARIA VENTURE: Annual Report (2003).
   Google Scholar
• FALCO EA, GOODWIN LG, HITCHINGS GH, ROLLO IM, RUSSELL PB: 2:4-diaminopyrimidines- a new series of antimalarials. Br. Pharmacol (1951) 6(2):185–200.
   PubMed Web of Science ®Google Scholar
• ROPER C, PEARCE R, NAIR S et al: Intercontinental spread of pyrimethamine-resistant malaria. Science (2004) 305(5687):1124.
   PubMed Web of Science ®Google Scholar
• HAYTON K, SU XZ: Genetic and biochemical aspects of drug resistance in malaria parasites. Curl: Drug Targets Infect. Disord. (2004) 4(1):1–10.
   PubMedGoogle Scholar
• GASASIRA AF, DORSEY G, NZARUBARA B et al: Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am. I Trop. Med. Hyg. (2003) 68(2):127–132.
   PubMed Web of Science ®Google Scholar
• DORSEY G, NJAMA D, KAMYA MR et al.: Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet (2002) 360(9350):2031–2038.
   PubMed Web of Science ®Google Scholar
• SCHWOBEL B, JORDAN S, VANISAVETH V et al.: Therapeutic efficacy of chloroquine plus sulphadoxine/ pyrimethamine compared with monotherapy with either chloroquine or sulphadoxine/pyrimethamine in uncomplicated Plasmodium falciparum malaria in Laos. Trop. Med. Int. Health (2003) 8(1):19–24.
   PubMed Web of Science ®Google Scholar
• HOMBHANJE FW: Halofantrine versus quinine-Fansidar combination in the treatment of post-chloroquine falciparum parasitaemia. RN G. Med. 1 (1998) 41(3–4):112-115.
   Google Scholar
• NAVARATNAM V, MOHAMAD M, HUSSAIN S et al: Chemosuppression of malaria by the triple combination mefloquine/sulfadoxine/pyrimethamine: a field trial in an endemic area in Malaysia.
   Google Scholar
• •• Trans. R. Soc. Trop. Med. Hyg. (1989) 83(6):755–759.
   Google Scholar
• OBONYO CO, OCHIENG F, TAYLOR WR et al: Artesunate plus sulfadoxine-pyrimethamine for uncomplicated malaria in Kenyan children: a randomized, double-blind, placebo-controlled trial. Trans. R. Soc. Trop. Med. Hyg. (2003) 97(5):585–591.
   PubMed Web of Science ®Google Scholar
• ALLOUECHE A, BAILEY W, BARTON Set al.: Comparison of chlorproguanil-dapsone with sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet (2004) 363(9424):1843–1848.
   Google Scholar
• LANG-UNNASCH N, MURPHY AD: Metabolic changes of the malaria parasite during the transition from the human to the mosquito host. Ann. Rev Microbiol (1998) 52:561–590.
   PubMed Web of Science ®Google Scholar
• DAUBENBERGER CA, POLTL-FRANK F, JIANG G et al: Identification and recombinant expression of glyceraldehyde-3-phosphate dehydrogenase of Plasmodium falciparum. Gene (2000) 246(1-2):255–264.
   PubMed Web of Science ®Google Scholar
• LEENSTRA T, TER KUILE FO, KARIUKI SK et al: Dehydroepiandrosterone sulfate levels associated with decreased malaria parasite density and increased hemoglobin concentration in pubertal girls from western Kenya../. Infect. Dis. (2003) 188(2):297–304.
   Google Scholar
• LI GQ, GUO XB, JIN R, WANG ZC, JIAN HX, LI ZY:Clinical studies on the treatment of malaria with qinghaosu and its derivatives. China Cooperative Research Group on qinghaosu and its derivatives as antimalarials. I Tradit. ChM. Med. (1982) 2(1):45–50.
   Google Scholar
• ••This report showed that artemisinininhibits the activity of the Ca2'-dependent ATPase of the parasite.
   Google Scholar
• ECKSTEIN-LUDWIG U, WEBB RJ, VAN GOETHEM ID et al: Artemisinins target the SERCA of Plasmodium fakiparum. Nature (2003) 424(6950:957–961.
   PubMedGoogle Scholar
• WHO: Meeting on Antimalarial drug development. (2002).
   Google Scholar
• ADJUIK M, BABIKER A, GARNER P et al.: Artesunate combinations for treatment of malaria: meta-analysis. Lancet (2004) 363(9402):9–17.
   PubMed Web of Science ®Google Scholar
• •This article provides a comprehensive analysis of all artemisinin-based clinical trials conducted to date.
   Google Scholar
• LIN AJ, KLAYMAN DL, MILHOUS WK: Antimalarial activity of new water-soluble dihydroartemisinin derivatives. J. Med. Chem. (1987) 30(10:2147–2150.
   PubMedGoogle Scholar
• LI QG, PEGGINS JO, LIN AJ et al: Pharmacology and toxicology of artelinic acid: preclinical investigations on pharmacokinetics, metabolism, protein and red blood cell binding, and acute and anorectic toxicities. Trans. R. Soc. Trop. Med. Hyg. (1998) 92(3):332–340.
   PubMed Web of Science ®Google Scholar
• VAN VIANEN PH, KLAYMAN DL, LIN AJ et al.: Plasmodium berghet the antimalarial action of artemisinin and sodium artelinate in vivo and in vitro, studied by flow cytometry. Exp. Parasitol (1990) 70(2):115–123.
   PubMed Web of Science ®Google Scholar
• O'NEILL PM, MILLER A, BISHOP LP et al.: Synthesis, antimalarial activity, biomimetic iron(II) chemistry, and in vivo metabolism of novel, potent C-10-phenoxy derivatives of dihydroartemisinin. J. Med. Chem. (2001) 44(0:58–68.
   Google Scholar
• HINDLEY S, WARD SA, STORR RC et al.: Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues. ./. Med. Chem. (2002) 45(5):1052–1063.
   PubMed Web of Science ®Google Scholar
• POSNER GH, PLOYPRADITH P, PARKER MH et al: Antimalarial, antiproliferative, and antitumor activities of artemisinin-derived, chemically robust, trioxane dimers. ./. Med. Chem. (1999) 42(20:4275–4280.
   PubMedGoogle Scholar
• VENNERSTROM JL, ARBE-BARNES S, BRUN R et al.: Identification of an antimalarial synthetic trioxolane drug development candidate. Nature (2004) 430(7002):900–904.
   PubMed Web of Science ®Google Scholar
• CHAKRABARTI D, DA SILVA T, BARGER J et al: Protein farnesyltransferase and protein prenylation in Plasmodium falciparum. Biol. Chem. (2002) 277(44):42066–42073.
   Web of Science ®Google Scholar
• CHAKRABARTI D, AZAM T, DELVECCHIO C et al: Protein prenyl transferase activities of Plasmodium falciparum. Mol Biochem. Parasitol (1998) 94(2):175–184.
   PubMed Web of Science ®Google Scholar
• EASTMAN RT, WHITE J, HUCKE 0 et al: Resistance to a protein farnesyltransferase inhibitor in Plasmodium falciparum. I Biol. Chem. (2005) 280(14):13554–13559.
   Web of Science ®Google Scholar
• APFEL CM, LOCHER H, EVERS S et al: Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. (2001) 45(4):1058–1064.
   PubMed Web of Science ®Google Scholar
• HACKBARTH CJ, CHEN DZ, LEWIS JG et al: N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. (2002) 46(9):2752–2764.
   PubMed Web of Science ®Google Scholar
• BRACCHI-RICARD V, NGUYEN KT, ZHOU Y et al: Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch. Biochem. Biophys. (2001) 396(2) :162–170.
   PubMed Web of Science ®Google Scholar
• ANG KK, HOLMES MJ, HIGA T, HAMANN MT, KARA UA: In vivo antimalarial activity of the 0-carboline alkaloid manzamine A. Antimicrob. Agents Chemother. (2000) 44(6):1645–1649.
   PubMed Web of Science ®Google Scholar
• BOURSEREAU Y, COLDHAM I: Synthesis and biological studies of 1-amino 0-carbolines. Bioorg. Med. Chem. Lett. (2004) 14(23):5841–5844.
   PubMed Web of Science ®Google Scholar